$1.47 Billion in Sales Expected for Zoetis Inc (ZTS) This Quarter

Brokerages forecast that Zoetis Inc (NYSE:ZTS) will report $1.47 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Zoetis’ earnings, with the highest sales estimate coming in at $1.49 billion and the lowest estimate coming in at $1.43 billion. Zoetis posted sales of $1.35 billion in the same quarter last year, which would indicate a positive year over year growth rate of 8.9%. The business is expected to issue its next earnings results on Thursday, November 1st.

On average, analysts expect that Zoetis will report full year sales of $5.78 billion for the current fiscal year, with estimates ranging from $5.73 billion to $5.80 billion. For the next year, analysts forecast that the business will report sales of $6.28 billion per share, with estimates ranging from $6.15 billion to $6.36 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.06. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 EPS.

Several brokerages recently commented on ZTS. BMO Capital Markets reissued a “hold” rating and set a $82.00 price objective on shares of Zoetis in a research report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, July 27th. Stifel Nicolaus increased their price objective on shares of Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Bank of America increased their price objective on shares of Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Finally, Morgan Stanley increased their price objective on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $89.64.

In other Zoetis news, insider Roxanne Lagano sold 2,000 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $84.76, for a total transaction of $169,520.00. Following the transaction, the insider now owns 22,023 shares in the company, valued at approximately $1,866,669.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Roman Trawicki sold 8,266 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $92.53, for a total transaction of $764,852.98. The disclosure for this sale can be found here. Insiders have sold a total of 15,283 shares of company stock worth $1,366,924 in the last 90 days. Company insiders own 0.35% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in Zoetis by 6.7% during the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock valued at $3,429,736,000 after acquiring an additional 2,584,199 shares during the period. Polen Capital Management LLC lifted its stake in shares of Zoetis by 3.9% in the 2nd quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after purchasing an additional 351,447 shares during the period. Brown Advisory Inc. lifted its stake in shares of Zoetis by 0.3% in the 1st quarter. Brown Advisory Inc. now owns 7,226,660 shares of the company’s stock worth $603,499,000 after purchasing an additional 19,546 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Zoetis by 9.1% in the 2nd quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after purchasing an additional 529,666 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Zoetis by 1.4% in the 1st quarter. Northern Trust Corp now owns 5,948,527 shares of the company’s stock worth $496,762,000 after purchasing an additional 82,183 shares during the period. Institutional investors and hedge funds own 90.45% of the company’s stock.

NYSE:ZTS opened at $91.70 on Friday. The stock has a market capitalization of $44.92 billion, a PE ratio of 38.21, a price-to-earnings-growth ratio of 1.91 and a beta of 1.02. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50. Zoetis has a 1-year low of $59.64 and a 1-year high of $93.67.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, July 20th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s dividend payout ratio is currently 20.83%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply